Ziv-aflibercept in macular disease

British Journal of Ophthalmology

Volumn 99, Issue 8, 2015, Pages 1055-1059

  Mansour, Ahmad M ^a   I Al Ghadban, Sara ^a   Yunis, Muhammad H ^a   El Sabban, Marwan E ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PLACENTAL GROWTH FACTOR; POLYCARBONATE; RANIBIZUMAB; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BINDING AFFINITY; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STABILITY; FEMALE; HUMAN; MALE; MIDDLE AGED; OFF LABEL DRUG USE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA FOVEA; SYRINGE; VERY ELDERLY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COST BENEFIT ANALYSIS; DIABETIC RETINOPATHY; ECONOMICS; ENZYME LINKED IMMUNOSORBENT ASSAY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBRETINAL FLUID; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; OFF-LABEL USE; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SUBRETINAL FLUID; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84938741525     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-306319     Document Type: Article

References (27)

1. Schmid MK, Bachmann LM, Fäs L, et al. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol 2015;99:141-6.
2. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201.
3. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014;121:2247-54.
4. Jeng KW, Wilgucki J, Halperin S, et al. Retina specialists treating age-related macular degeneration recommend different approaches for patients than they would choose for themselves. Retina 2014;34:1796-801.
5. Silver J. Drugs for macular degeneration, price discrimination, and Medicare's responsibility not to overpay. JAMA 2014;312:23-4.
6. Trichonas G, Kaiser PK. Aflibercept for the treatment of age-related macular degeneration. Ophthalmol Ther 2013;2:89-98.
7. Ng DS, Kwok AK, Chan CW, et al. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients. Hong Kong Med J 2012;18:488-95.
8. Chen YH, Wu PC, Shiea J, et al. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. J Ocul Pharmacol Ther 2009;25:65-9.
9. Ornek K, Karahan ZC, Ergin A, et al. Bevacizumab sterility in multiple doses from a single-use vial. Ann Pharmacother 2008;42:1425-8.
10. Marmor MF, Martin LJ, Tharpe S. Osmotically induced retinal detachment in the rabbit and primate. Electron miscoscopy of the pigment epithelium. Invest Ophthalmol Vis Sci 1980;19:1016-29.
11. Sturner WQ, Dowdey AB, Putnam RS, et al. Osmolality and other chemical determinations in postmortem human vitreous humor. J Forensic Sci 1972;17:387-93.
12. Gagajewski A, Murakami MM, Kloss J, et al. Measurement of chemical analytes in vitreous humor: Stability and precision studies. J Forensic Sci 2004;49:371-4.
13. Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol 2014;98(Suppl 1):i11-16.
14. Klettner A, Tahmaz N, Dithmer M, et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. Br J Ophthalmol 2014;98:1448-52.
15. de Oliveira Dias JR, Badaró E, Novais EA, et al. Preclinical investigations of intravitreal ziv-aflibercept. Ophthalmic Surg Lasers Imaging Retina 2014;45: 577-84.
16. Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol 2006;142:141-3.
17. Stein JD, Newman-Casey PA, Mrinalini T, et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 2014;121:936-45.
18. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-6.
19. Yannuzzi NA, Klufas MA, Quach L, et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol 2015;133:32-9.
20. Paul M, Vieillard V, Roumi E, et al. Long-term stability of bevacizumab repackaged in 1 mL polypropylene syringes for intravitreal administration. Ann Pharm Fr 2012;70:139-54.
21. Signorello L, Pucciarelli S, Bonacucina G, et al. Quantification, microbial contamination, physico-chemical stability of repackaged bevacizumab stored under different conditions. Curr Pharm Biotechnol 2014;15:113-19.
22. Palmer JM, Amoaku WM, Kamali F. Quality of bevacizumab compounded for intravitreal administration. Eye 2013;27:1090-7.
23. Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol 2013;7:495-501.
24. Ahn SJ, Ahn J, Park S, et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2014;55:567-73.
25. Moisseiev E, Waisbourd M, Ben-Artsi E, et al. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefes Arch Clin Exp Ophthalmol 2014;252:331-7.
26. Hahn P, Kim JE, Stinnett S, et al. Aflibercept-related sterile inflammation. Ophthalmology 2013;120:1100-1.
27. Bailey C, Aloumanis V, Walker B, et al. Stability of preoperative cataract surgery gel in polycarbonate syringes. Int J Pharm Compd 2009;13:564-8.